Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 431-090-3 | CAS number: 190085-41-7
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Salicylate derivatives such as the subject material are expected to be well absorbed following oral or inhalation exposures but poorly absorbed following dermal exposures. Once absorbed, metabolism is expected to be rapid with elimination predominantly through the urine. Bioaccumulation is not expected.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 10
- Absorption rate - inhalation (%):
- 100
Additional information
The metabolic fates of a number of salicylate esters have been investigated, including the structurally similar 2 -ethylhexyl salicylate (CAS 118 -60 -5), and have been found to be rapidly and completely metabolized by esterases common in many tissues including skin, plasma, liver and other body tissues (Belsito et al., 2007). The products of this metabolism are salicylic acid and the corresponding alcohol. Salicylic acid is rapidly and completely eliminated in a number of species with elimination almost exclusively in the urine (Belsito et al., 2007). Although information is lacking, it is assumed that the alcohol metabolite, 2 -hexyloctyl aclcohol, will be rapidly metabolized and eliminated and, due to low toxicity, will not contribute to the toxicological hazard of the subject material (OECD, 2006). The oral bioavailability of the subject material is assumed to be 100%. Although inhalation toxicokinetic data is lacking, it is presumed that absorption following inhalation exposures will equal that of oral exposures (100%). Based on physical-chemical properties as well as limited data for similar salicylate esters, dermal absorption of the subject material is expected to be low. A conservative estimate of 10% is assigned for dermal absorption. Regardless of route of exposure, bioaccumulation of the subject material or its metabolites is not anticipated.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
